Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 13/20 | 0.62 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.51 |
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | CSF1R | P07333 | 4/20 | 0.46 |
| ▸ | KIT | P10721 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | NRAS | P01111 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24231304 | 1.00 | FLT3 (0.62) | FLT3IRAK4KDRCSF1RKIT | |
| SCHEMBL24231329 | 0.93 | FLT3 (0.58) | FLT3IRAK4KDRCSF1RKIT | |
| SCHEMBL25991512 | 0.93 | FLT3 (0.58) | FLT3IRAK4KDRCSF1RKIT | |
| SCHEMBL24975664 | 0.89 | FLT3 (0.50) | FLT3IRAK4KDRCSF1RKIT | |
| SCHEMBL24231529 | 0.89 | FLT3 (0.79) | FLT3IRAK4KDRCSF1RKIT | |
| SCHEMBL25989694 | 0.89 | FLT3 (0.79) | FLT3IRAK4KDRCSF1RKIT | |
| SCHEMBL25989696 | 0.89 | FLT3 (0.79) | FLT3IRAK4KDRCSF1RKIT | |
| SCHEMBL26357431 | 0.88 | FLT3 (0.53) | FLT3IRAK4KDRCSF1RKIT | |
| SCHEMBL26358072 | 0.88 | FLT3 (0.53) | FLT3IRAK4KDRCSF1RKIT | |
| SCHEMBL31557797 | 0.87 | FLT3 (0.47) | FLT3IRAK4KDRCSF1RKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150601-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-08-10 | — | — | WO | disclosed |